Results 211 to 220 of about 31,641,461 (330)
Successful Mediastinal Cryobiopsy Using the Slim UCP190F EBUS Bronchoscope and a 25G Needle: Demonstrating the Efficacy of the Ariza-Pallares Approach. [PDF]
Onyancha S, Rohde G.
europepmc +1 more source
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Clarifying the Diagnostic Criteria for Lemierre Syndrome. [PDF]
Yale SH, Tekiner H, Yale ES.
europepmc +1 more source
Palmoplantar aquagenic urticaria: A case report
Prachi Srivastava +3 more
openalex +1 more source
A case of esophageal and endobronchial anthracosis [PDF]
Ju Yang +10 more
openalex +1 more source
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada. [PDF]
Mital S +4 more
europepmc +1 more source
Official bilingualism and indigenous language loss: the case of Cameroon.
Raymond Echitchi
openalex +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source

